Clinical Trial Update: Combined Use of BCG and Interferon Alpha in Bladder Cancer [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 clinical trial evaluating the combination of Bacillus Calmette-Guérin (BCG) and Interferon Alpha for superficial bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• BCG (Bacillus Calmette-Guérin) (Bacillus Calmette-Guérin)
• Interferon-alpha (interferon alpha)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Carcinoma of Urinary Bladder, Superficial | Phase 2, Phase 3 | Status: COMPLETED